Related Experiment Video

Updated: Apr 29, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

26.7K

Fecal microbiota transplantation in children with recurrent Clostridium difficile infection

Anne Pierog1, Ali Mencin, Norelle Rizkalla Reilly

  • 1From the Columbia University Medical Center, Division of Pediatric Gastroenterology, Hepatology and Nutrition, New York, NY.

The Pediatric Infectious Disease Journal
|May 24, 2014
PubMed

Insights

Fecal microbiota transplantation (FMT) effectively treated recurrent Clostridium difficile infections in six pediatric patients. This study shows FMT is a promising option for children with refractory C. difficile, though long-term outcomes require further investigation.

Area of Science:

  • Gastroenterology
  • Microbiology
  • Pediatric Infectious Diseases

Background:

  • Clostridium difficile infection (CDI) is a significant cause of healthcare-associated diarrhea.
  • Fecal microbiota transplantation (FMT) has shown high efficacy in treating recurrent CDI in adults.
  • Limited data exists on FMT for pediatric refractory CDI.

Purpose of the Study:

  • To evaluate the efficacy and safety of FMT in pediatric patients with refractory Clostridium difficile infections.
  • To assess the recurrence rates of CDI after FMT in a pediatric cohort.

Main Methods:

  • Retrospective case series of 6 pediatric patients with refractory CDI.
  • FMT administered via various routes (colonoscopy, enema, nasogastric tube).
  • Clinical cure and recurrence were monitored post-transplantation.

Main Results:

  • All 6 pediatric patients achieved clinical cure of CDI after FMT.
  • No recurrences of CDI were observed in the study cohort at the time of reporting.
  • FMT was generally well-tolerated in this pediatric population.

Conclusions:

  • Fecal microbiota transplantation is a potentially effective treatment for refractory Clostridium difficile infection in children.
  • FMT offers a viable therapeutic option for pediatric patients with recurrent or refractory CDI.
  • Further long-term studies are necessary to confirm the sustained safety and efficacy of FMT in pediatric populations.

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.6K
Murine Fecal Isolation and Microbiota Transplantation07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

5.6K

Related Concept Videos

Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
61
Microbiota of the Large Intestine01:27

Microbiota of the Large Intestine

The large intestine hosts the most densely populated microbial ecosystem in the human body. This complex community primarily consists of anaerobic bacteria, with Bacillota (formerly Firmicutes) and Bacteroidota (formerly Bacteroidetes) as the predominant groups. The distribution of these microbes varies along different sections of the large intestine, influenced by local environmental factors such as oxygen availability and nutrient composition.The cecum, located at the beginning of the large...
96
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K